CDC-RFA-DD22-2202: I-FASD: Understanding Clinical Data and Pathways to Inform Surveillance of Children with Fetal Alcohol Spectrum Disorders
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCBDDD notices from 2022.
Centers for Disease Control - NCBDDD offered grants of up to $450,000 to any type of organization. It expected to make about 3 awards worth $4.0 million in total. Applications closed on May 2, 2022.
From the official notice on Grants.gov, last changed March 2, 2022. Checked November 7, 2026.
- Award ceiling$450,000
- Total funding$4.0 million
- Expected awards3
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 2, 2022 |
|---|---|
| Deadline | May 2, 2022 |
| Archived by Grants.gov | June 1, 2022 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
N/A
Is this a realistic fit?
- Past Birth Defects and Developmental Disabilities - Prevention and Surveillance awards averaged $930,644; this notice allows up to $450,000 per award.
- Most of the program's money (29% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Fetal Alcohol Spectrum Disorders (FASDs) are a group of overlapping diagnoses that can occur in a person who was prenatally exposed to alcohol. Public health surveillance of children with FASDs is essential for understanding the magnitude of these conditions in the population, as well as understanding associated needs, healthcare utilization, and comorbidities. Information from existing healthcare data systems (including electronic medical records and electronic claims databases) are a potential source of surveillance data, but a better understanding of these data, and the processes and pathways by which children with a potential FASD are referred, evaluated, and receive care are needed. This non-research surveillance NOFO will work with clinical sites that have experience evaluating, diagnosing, or providing care to children with FASDs to: (1) identify, describe, and abstract information from data sources that contain relevant healthcare related information about children referred, evaluated, or diagnosed with FASDs; (2) characterize the availability and quality of healthcare related data, as well as opportunities for using healthcare related information for public health surveillance; and (3) describe and assess processes and pathways for identifying, referring, evaluating and diagnosing children with a potential FASD. Findings from this NOFO will be used to inform future surveillance activities.
Who has won Birth Defects and Developmental Disabilities - Prevention and Surveillance grants before
From fiscal 2021 to 2025, Birth Defects and Developmental Disabilities - Prevention and Surveillance (93.073) awarded $94.9 million across 102 grant awards, an average of $930,644 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 2 | $5.7 million |
| University of North Carolina at Chapel Hill | North Carolina | 4 | $4.9 million |
| University of Texas at Austin | Texas | 2 | $4.2 million |
| Massachusetts Department of Public Health | Massachusetts | 3 | $3.6 million |
| The University of Iowa | Iowa | 3 | $3.5 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DD22-2202 still open?
No. It closed on May 2, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for I-FASD: Understanding Clinical Data and Pathways to Inform Surveillance of Children with Fetal Alcohol Spectrum Disorders?
Centers for Disease Control - NCBDDD accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for I-FASD: Understanding Clinical Data and Pathways to Inform Surveillance of Children with Fetal Alcohol Spectrum Disorders?
Closed May 2, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $450,000 each. About $4.0 million in total across about 3 awards.
Who has won Birth Defects and Developmental Disabilities - Prevention and Surveillance grants before?
The largest recipients over five fiscal years were The Johns Hopkins University, University of North Carolina at Chapel Hill, University of Texas at Austin. The program made 102 awards worth $94.9 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)